Prevention of carotid artery thrombosis by oral platelet GPIIb/IIIa antagonist in dogs

Stroke

Volumn 28, Issue 4, 1997, Pages 830-836

  Mousa, Shaker A ^a   Mu, Dun Xue ^a   Lucchesi, Benedict R ^a,b  

^a DUPONT COMPANY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

antiplatelet agents; antithrombotic therapy; carotid arteries; dogs; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARGINYLGLYCYLASPARTIC ACID; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; INTEGRIN; PROCOAGULANT; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING TIME; BLOOD CELL COUNT; BLOOD PRESSURE; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DOG; DRUG CAPSULE; DRUG EFFICACY; DRUG POTENCY; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION;

EID: 0030889610     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.28.4.830     Document Type: Article

References (35)

1. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981; 304:685-691.
2. Rubenstein MD, Wall RT, Baim DS, Harrison DC. Platelet activation in clinical coronary artery disease and spasm. Am Heart J. 1981;102:363-367.
3. Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP. Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol. 1981;48:395-402.
4. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
5. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J Am Coll Cardiol. 1985;5:175B-184B.
6. Travis J. Biotech gets a grip on cell adhesion: frontier in biotechnology. Science. 1993;260:906-908.
7. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
8. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br Heart J. 1985;53:363-373.
9. Hamm CW, Bliefield W, Kupper W, Lorenz RL, Weber PC, Wober W. Biochemical evidence of platelet activation in patients with persistent unstable angina. J Am Coll Cardiol. 1987;10:998-1004.
10. Ashby B, Daniel JL, Smith JB. Mechanisms of platelet activation and inhibition. Hematol Oncol Clin North Am. 1990;4:1-26.
11. Saltiel E, Ward A. Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs. 1987;34:222-262.
12. Golino P, Ashton JH, Glas-Greenwalt P, McNatt J, Buja LM, Willerson JT. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with t-PA in a canine preparation of coronary thrombosis. Circulation. 1988;77:678-684.
13. Walenga JM, Pifarra R, Fareed J. Recombinant hirudin as an antithrombotic agent. Drugs of Future. 1990; 15:267-270.
14. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TTMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76: 142-154.
15. John JA, Gold HK, Leinbach RC, Yasuda T, Gimple LW, Werner W, Finkelstein D, Newell J, Ziskind AA, Collen D. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. Circulation. 1988;78:546-556.
16. Pytela R, Pierschbacher MS, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of RGD specific adhesion receptors. Science. 1986;231:1559-1562.
17. Philips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell. 1991;65:359-362.
18. D'Souza SE, Ginsberg MH, Burke TA, Plow EF. The ligand binding site of the platelet integrin receptor GPIIb-IIIa is proximal to the second calcium binding domain of its a subunit. J Biol Chem. 1990;265:3440-3446.
19. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang IK, Holt R, Fallon JT, Collen D. Comparison effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 1990;16: 714-722.
20. Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor in an experimental animal model. Blood. 1986;68:783-786.
21. Gold HK, Gimple LW, Yasuda T, Leinbach RC, Werner W, Holt R, Jordon R, Berger H, Collen D, Coller BS. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa, in patient with unstable angina pectoris. J Clin Invest. 1990;86:651-659.
22. Mousa SA, Topol EJ. Recent advances in the development of platelet GPIIb/IIIa receptor antagonists. In: Holmes D, ed. Current Review of Interventional Cardiology. Philadelphia, Pa: Current Medicine; 1996:113-129.
23. Reverter JC, Beguin S, Kessels H, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest. 1996,98:863-874.
24. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J. MK383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993;88(4 pt 1):1512-1517.
25. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mée CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. Circulation. 1995,91:2151-2157.
26. Topol EJ. Novel antithrombotic approaches to coronary artery diseases. Am J Cardiol. 1995;75:27b-33b.
27. Mousa SA, Bozarth JM, Forsythe MS, Jackson S, Leamy A, Diemer M, Kapil R, Knabb R, Mayo M, De Grado WF, Pierce SK, Thoolen MJ, Reilly TM. Antiplatelet and antithrombotic efficacy of DMP728, a novel platelet GPIIb/IIIa antagonist. Circulation. 1994; 89:3-12.
28. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res. 1980;17: 841-853.
29. Mousa SA, Bozarth JM, Forsythe MS, Lorelli W, Ramachandran N, Jackson S, De Grado W, Reilly TM. Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Cardiology. 1993;83:374-382.
30. Mousa SA, Reilly TM. Antiplatelet effects of direct acting thrombin inhibitors and platelet GPIIb-IIIa antagonists: comparative analysis. In: Gallo LL, ed. Cardiovascular Disease 2. New York, NY: Plenum Press; 1995:255-268.
31. Rote W, Mu D-X, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model, II: adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol. 1993;23:203-211.
32. Gold HK, Torres FW, Garabedian HD, Werner W, Jang I. Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina. J Am Coll Cardiol. 1993;21:1039-1047.
33. Mousa SA. Antiplatelet/antithrombotic effects of platelet GPIIb/IIIa receptor antagonists, thrombin inhibitors, and aspirin: comparative analysis. In: Zavoico G, Sussman C, Savage L, eds. Advances in Anticoagulant and Thrombolytic Therapies. Southborough, Mass: IBC Biomedical Library Series; 1996:1-19.
34. Rote WE, Nedelman MA, Mu D-X, Manley PJ, Weisman H, Cunningham MR, Lucchesi BR. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke. 1994;25: 1223-1233.
35. Rosenblum WI, Nelson GH, Wormley B, Werner P, Wang J, Shih CY. Role of platelet-endothelial cell adhesion molecule (PECAM) in platelet adhesion/aggregation over injured but not denuded endothelium in vivo and ex vivo. Stroke. 1996;27:709-711.